Superworth

Rigel Pharmaceuticals free cash flow RIGL

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Dec 31, 2022
−$74.2M
Latest quarter, Q4 FY22
−$22M
Fiscal year 2022
−$74.2M
−1513% on the year before

Rigel Pharmaceuticals' free cash flow was −$74.2M over the twelve months to Dec 31, 2022, down 1513% on a year earlier.

In its latest quarter, Q4 FY22, it was −$22M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2022−$74.2M−1513%
FY2021$5.3Mn/a
FY2020−$53.4Mn/a
FY2019−$43Mn/a
FY2018−$59.9Mn/a
FY2017−$77.7Mn/a
FY2016−$76.7Mn/a
FY2015−$24Mn/a
FY2014−$70.2Mn/a
FY2013−$87.3Mn/a
FY2012−$88.6Mn/a
FY2011−$71.7Mn/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY22−$22Mn/a−$74.2M
Q3 FY22−$13.5Mn/a−$71.3M
Q2 FY22−$12.9M−123%−$68.3M
Q1 FY22−$25.9Mn/a−$584K
Q4 FY21−$19.1Mn/a$5.3M
Q3 FY21−$10.5Mn/a$8.2M
Q2 FY21$54.8Mn/a−$970K
Q1 FY21−$20Mn/a−$69.8M
Q4 FY20−$16.1Mn/a−$53.4M
Q3 FY20−$19.7Mn/a−$47.6M
Q2 FY20−$14Mn/a−$42.9M
Q1 FY20−$3.7Mn/a−$45.7M

Against its peers

Companies in Drug Manufacturers - General nearest Rigel Pharmaceuticals' size, closest first, today.

CompanyFree cash flow yield
RIGLRigel Pharmaceuticalsn/m
ABUSArbutus Biopharman/m
AMPHAmphastar Pharmaceuticals14.3%
COLLCollegium Pharmaceuticaln/m
OMEROmeros−5.7%
CRMDCorMedixn/m
ZVRAZevra Therapeutics5.6%
IRWDIronwood Pharmaceuticalsn/m
PBYIPuma Biotechnology7.2%
PCRXPacira BioSciences12.4%
ANABAnaptysbion/m
Peer median7.2%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Rigel Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.